Method for sensitizing bovine mammary cells to respond to LPS

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100

Reexamination Certificate

active

07361351

ABSTRACT:
Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNFα mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.

REFERENCES:
patent: 5543303 (1996-08-01), Goyert
patent: 5804189 (1998-09-01), Goyert
patent: 5869055 (1999-02-01), Juan et al.
Mikayama et al: (PNAS, 1993. 90: 10056-10060.
Burgess et al (J Cell Biol. 111:2129-2138, 1990.
Lazar et al. Mol Cell Biol. 8:1247-1252, 1988.
Wang et al. JBC, 2001 276:49213-49220.
Haziot, A., et al., “Recombinant Soluble CD14 Inhibits LPS-Induced Tumor Necrosis Factor-α Production by Cells in Whole Blood”,J. of Immunology, vol. 152, pp. 5868-5876, 1994.
Haziot, A., et al., “Recombinant Soluble CD14 Mediates the Activation of Endothelial Cells by Lipopolysaccharide”,J. of Immunology, vol. 151, pp. 1500-1507, 1993.
Haziot, A., et al., “Recombinant Soluble CD14 Prevents Mortality in Mice Treated with Endotoxin (Lipopolysaccharide)”,J. of Immunology, vol. 154, pp. 6529-6532, 1995.
Ikeda, A., et al., “Molecular Cloning of Bovine CD14 gene”,J. Vet. Med. Sci., vol. 59, (8), pp. 715-719, 1997.
Majerle, A., et al., “Expression and Refolding of Functional Fragments of the Human Lipopolysaccharide Receptor CD14 inEscherichia coliandPichia pastoris”, Protein Expression and Purification, vol. 17, pp. 96-104, 1999.
Stelter, F., et al., “Different Efficacy of Soluble CD14 Treatment in High-and Low-Dose LPS Models”,European J. of Clinical Investigation, vol. 28, pp. 205-213, 1998.
Takai, N., et al., “Primary Structure of Rat CD14 and Characteristics of Rat CD14, Cytokine, and NO Synthase mRNA Expression in Mononuclear Phagocyte System Cells in Response to LPS”,J. Of Leukocyte Biology, vol. 61, pp. 736-744, 1997.
Tapping, R.I., et al., “Cellular Binding of Soluble CD14 Requires Lipopolysaccharide (LPS) and LPS-binging Protein”,Department of Immunology, Abstract, vol. 272, (37), pp. 23157-23164, Sep. 12, 1997.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for sensitizing bovine mammary cells to respond to LPS does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for sensitizing bovine mammary cells to respond to LPS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for sensitizing bovine mammary cells to respond to LPS will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2758044

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.